Soligenix (SNGX) Cash from Financing Activities (2010 - 2026)
Soligenix's (SNGX) quarterly Cash from Financing Activities came in at $451000.0 in Q1 2026, down 65.95% YoY from $1.3 million in Q1 2025, and up 185.65% on a QoQ basis from $157884.0 in Q4 2025.
Soligenix (SNGX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 15 years of Cash from Financing Activities data on file, last reported at $451000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 65.95% year-over-year to $451000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (up 4.61% YoY) and the FY2025 annual result came in at $10.4 million, up 33.84% from the prior year.
- Cash from Financing Activities advanced to $451000.0 in Q1 2026, from $157884.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $8.4 million in Q3 2025 to a low of -$931558.0 in Q1 2023.
- A 4-year average of $1.7 million and a median of $451000.0 in 2026 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 14831.64% in 2025, down 87.12% in 2025.
- Tracing SNGX's Cash from Financing Activities over 4 years: stood at -$46182.0 in 2023, then jumped by 625.91% to $242878.0 in 2024, then plunged by 34.99% to $157884.0 in 2025, then soared by 185.65% to $451000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $451000.0 (Q1 2026), $157884.0 (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | 5.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.49 Mn |
| Jun 30, 2026 | 5.49 Mn |
| Mar 31, 2026 | 451,000.00 |
| Mar 31, 2026 | 451,000.00 |
| Dec 31, 2025 | 157,884.00 |
| Dec 31, 2025 | 157,884.00 |
| Sep 30, 2025 | 8.36 Mn |
| Sep 30, 2025 | 8.36 Mn |
| Jun 30, 2025 | 545,635.00 |
| Jun 30, 2025 | 545,635.00 |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 242,878.00 |
| Dec 31, 2024 | 242,878.00 |
| Sep 30, 2024 | 3.29 Mn |
| Sep 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 4.23 Mn |
| Jun 30, 2024 | 4.23 Mn |
| Mar 31, 2024 | -8,992.00 |
| Mar 31, 2024 | -8,992.00 |